福泰制药Vertex Pharmaceuticals Inc. (VRTX) 2002年10-K年度报告「NASDAQ」.pdf

1、 Use these links to rapidly review the document FORM 10-K INDEX VERTEX PHARMACEUTICALS INCORPORATED Index to Consolidated Financial Statements 2003.EDGAR Online,Inc.UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR15(d)OF

2、THE SECURITIESEXCHANGE ACT OF 1934 For the Fiscal Year Ended December31,2002 or TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d)OFTHE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto Commission file number 000-19319 Vertex Pharmaceuticals Incorporated(Exact name of registrant as speci

3、fied in its charter)Massachusetts 04-3039129(State of incorporation)(I.R.S.Employer Identification No.)130 Waverly Street Cambridge,Massachusetts 02139-4242(Address of principal executive offices)(Zip Code)(617)444-6100(Registrants telephone number,including area code)Securities registered pursuant

4、to Section12(b)of the Exchange Act:None Securities registered pursuant to Section12(g)of the Exchange Act:Common Stock,$0.01 Par Value Per Share(Title of class)Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange

5、Act of 1934 during the preceding 12months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90days.Yes XNo Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of RegulationS-K i

6、s not contained herein,and will not be contained,to the best of the registrants knowledge,in definitive proxy or information statements incorporated by reference in PartIII of this Form10-K or any amendment to this Form10-K.X Indicate by check mark whether the registrant is an accelerated filer(as d